FDA panel votes against Intercept’s liver med Ocaliva; Lilly’s Ebglyss wins approval for eczema
Intercept Pharmaceuticals
faced a major setback as a US Food and Drug Administration (FDA) panel voted
against the confirmato...
Impressions : 1205
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.